



**Ref. No.:** EIKO/BSE/2024-25/42

**Date:** 21<sup>st</sup> October, 2024

To,  
Corporate Services Department,  
**BSE Limited**,  
Phiroze Jeejeebhoy Towers,  
1st Floor, Dalal Street,  
Fort, Mumbai - 400001.

Scrip Code: 540204

**Subject:** Newspaper Publication.

Dear Sir/ Madam,

Pursuant to Regulations 30 and 47 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed a copy of newspaper publication in the following newspapers with respect to Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30<sup>th</sup> September, 2024 approved at the meeting of Board of Directors held on Saturday, 19<sup>th</sup> October, 2024

1. Financial Express (English)
2. Mumbai Lakshadweep (Marathi)

Copy of the results are also uploaded on the website of our Company - [www.eikolifesciences.com](http://www.eikolifesciences.com) .


Kindly take the same on your records.

Thanking you,  
Yours sincerely.

**For Eiko Lifesciences Limited**

**Chintan Doshi**  
**Compliance officer & Company Secretary**  
**Encl: Same as above**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
N  
h  
i  
n  
o


 <b>EIKO LIFESCIENCES LIMITED</b> FEEL THE CHEMISTRY (CIN: L65993MH1977PLC258134) Regd off: 604, Centrum, Opp. TMC Office, Near Satkar Grand Hotel, Wagle Estate, Thane West MH 400604										
EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30-09-2024										
₹ in Lakhs except EPS										
Sr. No.	Particulars	Standalone					Consolidated			
		Quarter Ended		Half Year Ended		Year Ended	Quarter Ended		Half Year	
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)	30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2024 (Unaudited)
1	Total Income from Operations	766.98	1,101.26	644.09	1,888.25	1,297.59	2,810.54	828.58	1,101.26	1,929.84
2	Net profit/ (Loss) for the period before tax (before Exceptional and/ or extraordinary items)	28.03	46.13	16.16	74.15	27.03	98.42	35.26	46.13	81.38
3	Net profit/ (Loss) for the period before tax (After Exceptional and/ or extraordinary items)	28.03	46.13	16.16	74.15	27.03	98.42	35.26	46.13	81.38
4	Net profit/ (Loss) for the period after tax (After Exceptional and/ or extraordinary items)	20.81	34.68	12.09	55.49	20.10	75.15	25.78	34.68	60.46
5	Net profit after taxes and share of profit of Associates	-	-	-	-	-	-	2.37	2.45	4.82
6	Total comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax), share of profit of Associates and Other Comprehensive Income (after tax)	20.81	34.68	12.09	55.49	20.10	77.55	28.15	37.13	65.29
7	Paid up equity share Capital	1,287.28	1,287.28	997.95	1,287.28	997.95	1,287.28	1,287.28	1,287.28	1,287.28
8	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year.	-	-	-	-	-	3,780.54	-	-	-
9	Basic Earning Per Share (Not Annualised) (EPS in ₹)	0.16	0.27	0.12	0.43	0.24	0.73	0.22	0.29	0.51
9	Diluted Earning Per Share (Not Annualised) (EPS in ₹)	0.16	0.27	0.12	0.43	0.24	0.73	0.22	0.29	0.51

**Note**

- The above unaudited Standalone and Consolidated financial results for the quarter and half year ended 30th September 2024 were reviewed by the audit committee of the board on 19th October 2024 and thereafter approved by the board of directors of the company at their meeting held on 19th October 2024.
- The above is an extract of the details format of Quarter Ended Results filed with the stock exchange under Regulation 33 of SEBI (listing Obligations and Disclosure Requirements) Regulation, 2015. The full format of the Quarter ended Financial Results are available on stock exchange website at [www.bseindia.com](http://www.bseindia.com) and also on the company's website i.e., [www.eikolifesciences.com](http://www.eikolifesciences.com)
- During the period, the company successfully acquired a 25.01% equity stake in Reflux Pharmaceuticals Private Limited ("RPPL"), thereby making it an associate company of Eiko Lifesciences Limited. Additionally, the company has incorporated wholly owned LLP i.e., Eiko Scientific Solutions LLP. As a result, consolidated financial results have been prepared and presented for the Quarter and Half Year ending 30th September 2024. Since this is the first period in which consolidated financial statements are being reported, comparative figures for the previous financial year are not available.

For Eiko Lifesciences Limited  
Sd/-  
Laxmikant Kabra  
Chairman & Director  
DIN: 00061346

Date: 19-10-2024  
Place: Thane

		 <b>EIKO LIFESCIENCES LIMITED</b> FEEL THE CHEMISTRY (CIN: L65993MH1977PLC258134) Regd off: 604, Centrum, Opp. TMC Office, Near Satkar Grand Hotel, Wagle Estate, Thane West MH 400604								
		EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30-09-2024								
		(₹ in Lakhs except EPS)								
Sr. No.	Particulars	Standalone						Consolidated		
		Quarter Ended		Half Year Ended		Year Ended	Quarter Ended		Half Year	
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)	30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2024 (Unaudited)
1	Total Income from Operations	786.98	1,101.26	644.09	1,888.25	1,297.59	2,810.54	828.58	1,101.26	1,929.84
2	Net profit/ (Loss) for the period before tax (before Exceptional and/ or extraordinary items)	28.03	46.13	16.16	74.15	27.03	98.42	35.26	46.13	81.38
3	Net profit/ (Loss) for the period before tax (After Exceptional and/ or extraordinary items)	28.03	46.13	16.16	74.15	27.03	98.42	35.26	46.13	81.38
4	Net profit/ (Loss) for the period after tax (After Exceptional and/ or extraordinary items)	20.81	34.68	12.09	55.49	20.10	75.15	25.78	34.68	60.46
5	Net profit after taxes and share of profit of Associates	-	-	-	-	-	-	2.37	2.45	4.82
6	Total comprehensive Income for the period (Comprising Profit/Loss) for the period (after tax), share of profit of Associates and Other Comprehensive Income (after tax)	20.81	34.68	12.09	55.49	20.10	77.55	28.15	37.13	65.29
7	Paid up equity share Capital	1,287.28	1,287.28	997.95	1,287.28	997.95	1,287.28	1,287.28	1,287.28	1,287.28
8	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year.	-	-	-	-	-	3,780.54	-	-	-
9	Basic Earning Per Share (Not Annualised) (EPS in ₹)	0.16	0.27	0.12	0.43	0.24	0.73	0.22	0.29	0.51
9	Diluted Earning Per Share (Not Annualised) (EPS in ₹)	0.16	0.27	0.12	0.43	0.24	0.73	0.22	0.29	0.51

**Note**

- The above unaudited Standalone and Consolidated financial results for the quarter and half year ended 30th September 2024 were reviewed by the audit committee of the board on 19th October 2024 and thereafter approved by the board of directors of the company at their meeting held on 19th October 2024.
- The above is an extract of the details format of Quarter Ended Results filed with the stock exchange under Regulation 33 of SEBI (listing Obligations and Disclosure Requirements) Regulation, 2015. The full format of the Quarter ended Financial Results are available on stock exchange website at [www.bseindia.com](http://www.bseindia.com) and also on the company's website i.e., [www.eikolifesciences.com](http://www.eikolifesciences.com)
- During the period, the company successfully acquired a 25.01% equity stake in Reflux Pharmaceuticals Private Limited ("RPPL"), thereby making it an associate company of Eiko Lifesciences Limited. Additionally, the company has incorporated wholly owned LLP i.e., Eiko Scientific Solutions LLP. As a result, consolidated financial results have been prepared and presented for the Quarter and Half Year ending 30th September 2024. Since this is the first period in which consolidated financial statements are being reported, comparative figures for the previous financial year are not available.

For Eiko Lifesciences Limited  
Sd/-  
Laxmikant Kabra  
Chairman & Director  
DIN: 00061346

Date: 19-10-2024  
Place: Thane